
Psoriasis Drugs Market by Therapeutic Class (Interleukin Inhibitors, Tumor Necrosis Factor Inhibitor), Type of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, Tropical Therapies), Mechanism of Action, Route of Administration, Distribution Channe
Description
Psoriasis Drugs Market by Therapeutic Class (Interleukin Inhibitors, Tumor Necrosis Factor Inhibitor), Type of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, Tropical Therapies), Mechanism of Action, Route of Administration, Distribution Channel, Application - Global Forecast 2024-2030
The Psoriasis Drugs Market size was estimated at USD 9.67 billion in 2023 and expected to reach USD 10.83 billion in 2024, at a CAGR 12.07% to reach USD 21.48 billion by 2030.
Global Psoriasis Drugs Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Psoriasis Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Psoriasis Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Psoriasis Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc., Celgene Corporation, Dr.Reddy's Laboratories, Eli Lilly and Company, Johnson & Johnson Services, Inc., Leo Pharma AS, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Stiefel Laboratories Inc., Sun Pharmaceutical Industries Ltd, and Takeda Pharmaceutical Company Limited.
Market Segmentation & Coverage
This research report categorizes the Psoriasis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
Therapeutic Class
Interleukin Inhibitors
Tumor Necrosis Factor Inhibitor
Type of Treatment
Biologic Drugs
Small Molecule Systemic Drugs
Tropical Therapies
Mechanism of Action
Interleukin Inhibitors
PDE4 Inhibitors
TNF Alpha Inhibitors
Route of Administration
Oral
Parenteral
Topical
Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Application
Arthritis
Erythrodermic
Guttate
Intertriginous
Nail
Plaque
Pustular
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Psoriasis Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Psoriasis Drugs Market?
3. What are the technology trends and regulatory frameworks in the Psoriasis Drugs Market?
4. What is the market share of the leading vendors in the Psoriasis Drugs Market?
5. Which modes and strategic moves are suitable for entering the Psoriasis Drugs Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
180 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Psoriasis Drugs Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing prevalence of psoriasis
- 5.1.1.2. Rising geriatric population coupled with growing prevalence of plaque psoriasis and psoriatic arthritis
- 5.1.1.3. Ease of process of approval of psoriasis drugs
- 5.1.2. Restraints
- 5.1.2.1. High cost of treatment
- 5.1.3. Opportunities
- 5.1.3.1. Increase in psoriasis research and pipeline drugs
- 5.1.4. Challenges
- 5.1.4.1. Side effects of the medication
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Psoriasis Drugs Market, by Therapeutic Class
- 6.1. Introduction
- 6.2. Interleukin Inhibitors
- 6.3. Tumor Necrosis Factor Inhibitor
- 7. Psoriasis Drugs Market, by Type of Treatment
- 7.1. Introduction
- 7.2. Biologic Drugs
- 7.3. Small Molecule Systemic Drugs
- 7.4. Tropical Therapies
- 8. Psoriasis Drugs Market, by Mechanism of Action
- 8.1. Introduction
- 8.2. Interleukin Inhibitors
- 8.3. PDE4 Inhibitors
- 8.4. TNF Alpha Inhibitors
- 9. Psoriasis Drugs Market, by Route of Administration
- 9.1. Introduction
- 9.2. Oral
- 9.3. Parenteral
- 9.4. Topical
- 10. Psoriasis Drugs Market, by Distribution Channel
- 10.1. Introduction
- 10.2. Hospital Pharmacies
- 10.3. Online Pharmacies
- 10.4. Retail Pharmacies
- 11. Psoriasis Drugs Market, by Application
- 11.1. Introduction
- 11.2. Arthritis
- 11.3. Erythrodermic
- 11.4. Guttate
- 11.5. Intertriginous
- 11.6. Nail
- 11.7. Plaque
- 11.8. Pustular
- 12. Americas Psoriasis Drugs Market
- 12.1. Introduction
- 12.2. Argentina
- 12.3. Brazil
- 12.4. Canada
- 12.5. Mexico
- 12.6. United States
- 13. Asia-Pacific Psoriasis Drugs Market
- 13.1. Introduction
- 13.2. Australia
- 13.3. China
- 13.4. India
- 13.5. Indonesia
- 13.6. Japan
- 13.7. Malaysia
- 13.8. Philippines
- 13.9. Singapore
- 13.10. South Korea
- 13.11. Taiwan
- 13.12. Thailand
- 13.13. Vietnam
- 14. Europe, Middle East & Africa Psoriasis Drugs Market
- 14.1. Introduction
- 14.2. Denmark
- 14.3. Egypt
- 14.4. Finland
- 14.5. France
- 14.6. Germany
- 14.7. Israel
- 14.8. Italy
- 14.9. Netherlands
- 14.10. Nigeria
- 14.11. Norway
- 14.12. Poland
- 14.13. Qatar
- 14.14. Russia
- 14.15. Saudi Arabia
- 14.16. South Africa
- 14.17. Spain
- 14.18. Sweden
- 14.19. Switzerland
- 14.20. Turkey
- 14.21. United Arab Emirates
- 14.22. United Kingdom
- 15. Competitive Landscape
- 15.1. FPNV Positioning Matrix
- 15.2. Market Share Analysis, By Key Player
- 15.3. Competitive Scenario Analysis, By Key Player
- 16. Competitive Portfolio
- 16.1. Key Company Profiles
- 16.1.1. AbbVie Inc.
- 16.1.2. Amgen Inc.
- 16.1.3. AstraZeneca Plc
- 16.1.4. Bausch Health Companies Inc.
- 16.1.5. Celgene Corporation
- 16.1.6. Dr.Reddy's Laboratories
- 16.1.7. Eli Lilly and Company
- 16.1.8. Johnson & Johnson Services, Inc.
- 16.1.9. Leo Pharma AS
- 16.1.10. Merck & Co., Inc.
- 16.1.11. Novartis International AG
- 16.1.12. Pfizer Inc.
- 16.1.13. Stiefel Laboratories Inc.
- 16.1.14. Sun Pharmaceutical Industries Ltd
- 16.1.15. Takeda Pharmaceutical Company Limited
- 16.2. Key Product Portfolio
- 17. Appendix
- 17.1. Discussion Guide
- 17.2. License & Pricing
- FIGURE 1. PSORIASIS DRUGS MARKET RESEARCH PROCESS
- FIGURE 2. PSORIASIS DRUGS MARKET SIZE, 2023 VS 2030
- FIGURE 3. PSORIASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. PSORIASIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. PSORIASIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. PSORIASIS DRUGS MARKET DYNAMICS
- FIGURE 7. PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
- FIGURE 8. PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2023 VS 2030 (%)
- FIGURE 10. PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
- FIGURE 12. PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
- FIGURE 14. PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 16. PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
- FIGURE 18. PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 22. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 24. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 27. PSORIASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 28. PSORIASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.